Trials / Terminated
TerminatedNCT01019473
Efficacy, Safety and Tolerability of AFQ056 in Patients With Huntington's Disease in Reducing Chorea
A Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Oral Dose Titration Proof of Concept Study in Patients With Huntington's Disease to Assess the Efficacy, Safety and Tolerability of AFQ056 in Reducing Chorea
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 30 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the efficacy, safety and tolerability of AFQ056 when added to optimize standard therapy in patients that have Huntington's disease in reducing chorea.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AFQ056 | |
| DRUG | Placebo |
Timeline
- Start date
- 2009-11-01
- Primary completion
- 2011-08-01
- First posted
- 2009-11-25
- Last updated
- 2011-09-23
Locations
10 sites across 2 countries: Germany, United Kingdom
Source: ClinicalTrials.gov record NCT01019473. Inclusion in this directory is not an endorsement.